MaxCyte Inc
NASDAQ:MXCT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
D
|
Dhunseri Ventures Ltd
NSE:DVL
|
IN |
|
Leadtek Research Inc
TWSE:2465
|
TW |
MaxCyte Inc
Total Assets
MaxCyte Inc
Total Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
MaxCyte Inc
NASDAQ:MXCT
|
Total Assets
$202.5m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
31%
|
CAGR 10-Years
41%
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Total Assets
$110.3B
|
CAGR 3-Years
4%
|
CAGR 5-Years
10%
|
CAGR 10-Years
10%
|
|
|
Danaher Corp
NYSE:DHR
|
Total Assets
$83.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
2%
|
CAGR 10-Years
6%
|
|
|
Waters Corp
NYSE:WAT
|
Total Assets
$5.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
12%
|
CAGR 10-Years
2%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Total Assets
$12.8B
|
CAGR 3-Years
5%
|
CAGR 5-Years
6%
|
CAGR 10-Years
6%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Total Assets
$29.9B
|
CAGR 3-Years
6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
23%
|
|
MaxCyte Inc
Glance View
MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. The company is headquartered in Gaithersburg, Maryland. The company went IPO on 2016-03-29. The firm is focused on providing enabling platform technologies to advance cell-based research and development, as well as next-generation cell therapeutic discovery, development and commercialization. The firm has developed and commercialized its Flow Electroporation platform, which facilitates complex engineering of a variety of cells. Its ExPERT platform is based on its Flow Electroporation technology, which has been designed to address the cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. Its ExPERT platform consists of three instruments, which are known as the ATx, STx and GTx. The firm has also developed CARMA, a therapeutic platform based on transfecting mRNA into unstimulated cells for the development of immune cell therapies.
See Also
What is MaxCyte Inc's Total Assets?
Total Assets
202.5m
USD
Based on the financial report for Dec 31, 2025, MaxCyte Inc's Total Assets amounts to 202.5m USD.
What is MaxCyte Inc's Total Assets growth rate?
Total Assets CAGR 10Y
41%
Over the last year, the Total Assets growth was -15%. The average annual Total Assets growth rates for MaxCyte Inc have been -11% over the past three years , 31% over the past five years , and 41% over the past ten years .
